Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.

Seto, Takashi; Esaki, Taito; Hirai, Fumihiko; Arita, Shuji; Nosaki, Kaname; Makiyama, Akitaka; Kometani, Takuro; Fujimoto, Chinatsu; Hamatake, Motoharu; Takeoka, Hiroaki; Agbo, Felix; Shi, Xiaojin

Seto, Takashi; Esaki, Taito; Hirai, Fumihiko; Arita, Shuji; Nosaki, Kaname; Makiyama, Akitaka; Kometani, Takuro; Fujimoto, Chinatsu; Hamatake, Motoharu; Takeoka, Hiroaki; Agbo, Felix; Shi, Xiaojin.

Affiliation

Seto T; Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan. tseto@nk-cc.go.jp

Cancer Chemother Pharmacol ; 72(3): 619-27, 2013 Sep.

Article in En | MEDLINE | ID: mdl-23892959

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasms/drug therapy; Protein Kinases/drug effects; Protein Serine-Threonine Kinases/antagonists & inhibitors; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms/pathology; Thiophenes/administration & dosage; Urea/administration & dosage; Urea/analogs & derivatives; Gemcitabine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Kinases / Antineoplastic Combined Chemotherapy Protocols / Protein Serine-Threonine Kinases / Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Cancer Chemother Pharmacol Year: 2013 Document type: Article Affiliation country: Japan Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google